Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery

This single-center, stratified randomized double-blind trial tests tegileridine, a new pain drug, for pain relief after weight-loss surgery. Researchers will compare tegileridine with standard opioid pain medicine. Eligible patients having bariatric surgery will be randomly assigned to one of the two treatment groups. Patients and study teams will not know which treatment each participant receives. Participants will be grouped based on whether they have obstructive sleep apnea (OSA). The primary measurement is postoperative recovery quality in the first 24 hours after surgery using the QoR-15 survey. The study will also track pain scores, rescue pain medication use, and drug side effects for 7 days after surgery. There is no guaranteed benefit for participants. Study pain medicines may cause side effects. Doctors will provide rescue treatment for uncontrolled pain.

Inclusion Criteria: * Age 18 to 65 years old * Scheduled for elective bariatric surgery * American Society of Anesthesiologists (ASA) physical status I, II or III * Able to understand and complete the QoR-15 questionnaire * Provide written informed consent to participate in the study Exclusion Criteria: * Known allergy or hypersensitivity to opioids, tegileridine or sufentanil * Severe hepatic or renal dysfunction * Preoperative chronic opioid use * History of severe respiratory disease except obstructive sleep apnea * Pregnant or breastfeeding women * Participants who cannot complete postoperative follow-up * Participation in another interventional clinical trial within 30 days before surgery